

## Andreas Festa, MD

### ORIGINAL ARTICLES (Index Medicus, MEDLINE, and PubMed)

1. Kopp HP, Festa A, Hopmeier P, Schernthaner G: Evaluation einer neuen Methode zur Bestimmung von glykiertem Hämoglobin mittels monoklonaler Antikörper (DCA 2000). Wien Klin Wochenschr (1996) 108/1: 16-19.
2. Schnack C, Festa A, D'Assie A, Haber P, Schernthaner G: Abnormal pulmonary function in type 1 diabetes in relation to metabolic long term control and to incipient nephropathy. Nephron 1996 (74) 395-400.
3. Merio R, Festa A, Bergmann H, Eder T, Eibl N, Stacher-Janotta G, Weber U, Budka C, Heckenberg A, Bauer P, Francesconi M, Schernthaner G, Stacher G: Slow gastric emptying in insulin-dependent diabetes - relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 1997 (20): 419-23.
4. Festa A, Kopp HP, Schernthaner G, Menzel EJ: Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41:350-356, 1998
5. Festa A, Schmölder B, Schernthaner G, Menzel EJ: Differential expression of receptors for advanced glycation end products on monocytes in patients with IDDM. Diabetologia 41:674-680, 1998
6. Festa A, D'Agostino Jr. R, Mykkänen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance - The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol, 19:562-568, 1999
7. Festa A, D'Agostino R Jr., Mykkänen L, Tracy R, Howard B, Haffner SM: Low density lipoprotein (LDL) particle size is inversely related to plasminogen activator inhibitor-1 (PAI-1) levels - The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol, 19:605-610, 1999
8. Haffner SM, D'Agostino R Jr, Goff D, Howard BV, Festa A, Saad MF, Mykkänen L: Low density lipoprotein (LDL) size in African Americans, Hispanics, and non-Hispanic Whites. Arterioscler Thromb Vasc Biol, 19:2234-2240, 1999
9. Festa A, Krugluger W, Shnawa N, Hopmeier P, Haffner SM, Schernthaner G: Trp64Arg polymorphism of the  $\beta_3$ -adrenergic receptor gene in pregnancy - association with mild gestational diabetes mellitus. J Clin Endocrinol Metab, 84:1695-1699, 1999
10. Festa A, Shnawa N, Schernthaner G, Haffner SM: Proinsulin in pregnant women with normal glucose tolerance or mild gestational diabetes mellitus. Exp Clin Endocrinol Diab, 107:447-452, 1999

11. **Festa A**, Shnawa N, Krugluger W, Hopmeier P, Schernthaner G, Haffner SM: Relative hypoleptinemia in women with mild gestational diabetes mellitus. Diab Med, 16:656-62, 1999
12. Mykkänen L, Zaccaro DJ, Hales CN, **Festa A**, Haffner SM: The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia, 42: 1060-1066, 1999
13. **Festa A**, D'Agostino R Jr, Rautaharju P, O'Leary DH, Rewers M, Mykkänen L, Haffner SM: Is QT interval a marker of subclinical atherosclerosis in non-diabetic subjects? Stroke, 30: 1566-1571, 1999
14. **Festa A**, D'Agostino R Jr, Mykkänen L, Tracy RP, Hales CN, Howard BV, Haffner SM: Low density lipoprotein (LDL) particle size in relation to insulin, proinsulin, and insulin sensitivity. Diabetes Care, 22:1688-1693, 1999
15. Holzäpfel A, **Festa A**, Stacher-Janotta G, Shnawa N, Bergmann H, Wölfl G, Schernthaner G, Stacher G: Gastric emptying in type-2 diabetes before and after therapy readjustment: no influence of actual blood-glucose concentration. Diabetologia, 42:1410-1412, 1999
16. Haffner SM, Mykkänen L, **Festa A**, Burke J, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation, 101:975-80, 2000
17. **Festa A**, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation, 102:42-47, 2000
18. **Festa A**, D'Agostino R, Mykkänen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in non-diabetic and type-2 diabetic subjects. Kidney Int, 58:1703-10, 2000
19. **Festa A**, D'Agostino Jr. R, Hales CN, Mykkänen L, Haffner SM: Heart rate in relation to insulin sensitivity and insulin secretion in non-diabetic subjects. Diabetes Care, 23:624-628, 2000
20. **Festa A**, D'Agostino R, Rautaharju P, Mykkänen L, Haffner SM: Relation of systemic blood pressure, left ventricular mass, insulin sensitivity and coronary artery disease to QT interval duration in non-diabetic and type 2 diabetic subjects. Am J Cardiol, 86:1117-22, 2000
21. Krugluger W, **Festa A**, Shnawa N, Bucher J, Boltz-Nitulescu G, Schernthaner G, Hopmeier P: A serin/alanine polymorphism in the nucleotid-binding fold-2 of the

- sulfonylurea receptor is associated with enhanced glucose-induced insulin secretion during pregnancy. J Inherit Metab Dis, 23:705-12, 2000
22. Festa A, Schwarzmeier A, Grünberger W, Scherthner G: Anwendung eines sensitiven Verfahrens zur Diagnose des Gestationsdiabetes - metabolische und klinische Ergebnisse. Geburtsh Frauenheilk, 61:79-84, 2001
  23. Festa A, D'Agostino R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM: The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obesity, 25:1407-15, 2001
  24. Kopp HP, Festa A, Krugluger W, Scherthner G: Levels of sex-hormone binding globulin in women with gestational diabetes mellitus. Exp Clin Endocrinol Diab, 109: 365-9, 2001
  25. Festa A, D'Agostino R, Tracy RP, Haffner SM: Levels of acute phase proteins and plasminogen activator inhibitor-1 in relation to the development of type 2 diabetes mellitus. Diabetes 51:1131-1137, 2002
  26. Hanley A, Karter A, Festa A, D'Agostino R, Jr, Wagenknecht L, Savage P, Tracy R, Saad M, Haffner S: Factor analysis of metabolic syndrome using directly measured insulin sensitivity. Diabetes 51:2642-47, 2002
  27. Festa A, D'Agostino R, Jr, Tracy RP, Haffner SM: C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects. Diabet Med 19:939-43, 2002
  28. Pavo I, Jermendy G, Varkonyi T, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. J Clin Endocrinol Metab 88: 1637-45, 2003
  29. Festa A, D'Agostino R, Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 (PAI-1) genotype and PAI-1 levels in Blacks, Hispanics, and Non-Hispanic Whites. Circulation, 107:2422-2427, 2003
  30. Stacher G, Lenglinger J, Bergmann H, Schneider C, Brannath W, Festa A, Meghdadi S, Stacher-Janotta G. Impaired gastric emptying and altered intragastric meal distribution in diabetes mellitus related to autonomic neuropathy? Dig Dis Sci 48:1027-34, 2003
  31. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Scherthner G. Impact of Weight Loss on Inflammatory Proteins and their Association to the Insulin Resistance Syndrome in morbidly obese Patients. Arterioscler Thromb Vasc Biol, 23:1042-7, 2003

32. Haffner SM, D'Agostino R Jr, **Festa A**, Bergman RN, Mykkänen L, Karter A, Saad MF, Wagenknecht LE: Low insulin sensitivity ( $S_I=0$ ) in diabetic and non-diabetic subjects in the Insulin Resistance Atherosclerosis Study: Is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care, 26:2796-2803, 2003
33. **Festa A**, Hanley AJG, Tracy RP, D'Agostino R, Haffner SM: Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation, 108 1822-1830, 2003
34. **Festa A**, D'Agostino R, Hanley AJG, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in non-diabetic subjects with isolated impaired glucose tolerance (IGT) or isolated impaired fasting glucose (IFG). Diabetes, 53:1549-1555, 2004
35. Hanley AJG, **Festa A**, D'Agostino R Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes, 53:1773-1781, 2004
36. Winzer C, Wagner O, **Festa A**, Schneider B, Roden M, Bancher-Todesca D, Pacini G, Funahashi T, Kautzky-Willer A. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721-1727, 2004
37. Hanley AJG, Williams K, **Festa A**, Wagenknecht LE, D'Agostino RB Jr, Kempf J, Zinman B, Haffner SM. Elevations in markers of liver injury and risk of type 2 diabetes: the IRAS. Diabetes 53:2623-32, 2004
38. **Festa A**. Postprandial blood glucose excursions and low-grade inflammation. Int J Clin Pract 58(Suppl 142): 25-28, 2004
39. **Festa A**, Haffner SM. Inflammation and cardiovascular disease in patients with diabetes - lessons from the DCCT (Editorial). Circulation, 2005, 111:2414-2415
40. **Festa A**, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. Nuclear magnetic resonance (NMR) lipoprotein abnormalities in prediabetic subjects in the IRAS: Circulation 111:3465-72, 2005
41. Hanley AJ, Williams K, **Festa A**, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome. The Insulin Resistance Atherosclerosis Study. Diabetes 54:3140-7, 2005
42. Hanley AJ, Karter AJ, Williams K, **Festa A**, D'Agostino RB Jr, Wagenknecht LE, Haffner SM. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome. Circulation 112:3713-21, 2005

43. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753-1759, 2006
44. Festa A, Williams K, D'Agostino R, Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in non-diabetic and diabetic individuals. Diabetes 55:1114-1120, 2006
45. Nauck MA, Duran S, Johns D, Kim D, Festa A, Trautmann M. Effect of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulfonylurea and metformin. Diabetologia 50:259-67, 2007
46. Hanley AJ, Wagenknecht LE, Festa A, D'Agostino RB Jr, Haffner SM. Alanine Aminotransferase (ALT) and directly measured insulin sensitivity in a multi-ethnic cohort: The insulin resistance atherosclerosis study. Diabetes Care 30:1819-27, 2007
47. Festa A, Williams K, Hanley AJ, Haffner SM. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638-44, 2008
48. Olson NC, Callas PW, Hanley AJ, Festa A, Haffner SM, Wagenknecht LE, Tracy RP. Circulating levels of TNF- $\alpha$  are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin resistance Atherosclerosis Study. J Clin Endocrinol Metab 97:1032-40, 2012
49. Gallwitz B, Guzman J, Dotta F, Guerci B, Simo R, Basson BR, Festa A, Kiljanski J, Sapin H, Trautmann M, Scherthaner G. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomized controlled trial. Lancet 379(9833):2270-8, 2012
50. Lee CC, Lorenzo C, Haffner SM, Wagenknecht LE, Festa A, Goodarzi MO, Stefanovski D, Olson NC, Norris JM, Rewers MJ, Hanley AJ. The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 56:112-20, 2013
51. Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ. Longitudinal decline of  $\beta$ -cell function: comparison of a direct method vs a fasting surrogate measure: The Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 98:4152-9, 2013
52. Fu H, Curtis BH, Xie W, Festa A, Schuster DP, Kendall DM. Frequency and causes of hospitalization on older compared to younger adults with type 2 diabetes in the United States: A retrospective, claims-based analysis. J Diabetes Complications 2014, Feb 26; (14) 51-8.

53. Schernthaner G, Rosas-Guzman J, Dotta F, Guerci B, Simo R, **Festa A**, Kiljanski J, Gallwitz B. Treatment escalation options for patients with type 2 diabetes after failure of exenatide BID or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) Study. Diabetes Obes Metab 17(7):689-98, 2015
54. Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmán J, Dotta F, **Festa A**, Zhou M, Kiljański J. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol Sep 4;14:116, 2015
55. Lorenzo C, Hanley AJ, Rewers MJ, **Festa A**, Haffner SM. Lipoprotein heterogeneity may help to detect individuals with insulin resistance. Diabetologia 58:2765-73, 2015
56. Lorenzo C, **Festa A**, Hanley AJ, Wagenknecht LE, Rewers MJ, Karter AJ, Escalante A, Haffner SM. Novel Protein Glycan Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 40(3): 375-382, 2017
57. **Festa A**, Heller S, Seaquist E, Duan R, Hadjiyianni I, Fu H. Association between mild and severe hypoglycemia in people with Type 2 diabetes initiating insulin. J Diabetes Complications 31(6):1047-1052, 2017
58. Santaren ID, Watkins SM, Liese AD, Wagenknecht LE, Rewers MJ, Haffner SM, Lorenzo C, **Festa A**, Bazinet RP, Hanley AJ. Individual serum saturated fatty acids and markers of chronic subclinical inflammation: the Insulin Resistance Atherosclerosis Study. J Lipid Res 58(11):2171-2179, 2017
59. Heller S, Pratley R, Sinclair A, **Festa A**, Kiljanski J, Brusko C, Duan R, Heine RJ. Glycemic outcomes of an Individualized treatment approach for older vulnerable patients: A randomized, controlled study in type 2 diabetes Mellitus (IMPERIUM). Diabetes Obes Metab 20(1):148-156, 2018
60. Pratley RE, Rosenstock J, Heller SR, Sinclair A, Heine RJ, Kiljanski J, Brusko CS, Duan R, **Festa A**. Reduced glucose variability with glucose-dependent versus glucose-independent therapies despite similar glucose control and hypoglycemia rates in a randomized, controlled study of older patients with type 2 diabetes mellitus. J Diabetes Sci Technol 12(6):1184-1191, 2018
61. Sinclair AJ, Heller SR, Pratley RE, Duan R, Heine RJ, **Festa A**, Kiljanski J. Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes Obes Metab 22, 2020, in press